Richard Malamut Sells 590 Shares of Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock

Key Points

• Director Richard Malamut sold 590 shares at an average price of $20.92 on April 2 under a pre‑arranged Rule 10b5‑1 plan, reducing his holding by 2.11% to 27,422 shares (~$573,668).
• Institutional investors own 77.96% of Pelthos, with notable Q4 stake increases from Ikarian Capital (up 309.5% to 255,758 shares) and Boothbay Fund (up 279.8% to 80,680 shares), indicating strong institutional accumulation.
• Analysts are broadly positive — five Buy ratings and one Hold give a MarketBeat consensus of "Moderate Buy" with an average price target of $55, versus the recent stock price around $24.38.

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS - Get Free Report) Director Richard Malamut sold 590 shares of the stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $20.92, for a total value of $12,342.80. Following the transaction, the director owned 27,422 shares in the company, valued at approximately $573,668.24. This trade represents a 2.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Price Performance

NYSEAMERICAN PTHS traded up $3.98 on Monday, reaching $24.38. The stock had a trading volume of 28,715 shares, compared to its average volume of 8,812. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.15 and a current ratio of 2.05. The stock has a market capitalization of $81.92 million, a P/E ratio of -1.17 and a beta of 3.93. The stock's fifty day moving average is $22.86. Pelthos Therapeutics Inc. has a 1-year low of $9.00 and a 1-year high of $54.29.

Institutional Trading of Pelthos Therapeutics

Institutional investors have recently bought and sold shares of the company. Ikarian Capital LLC lifted its stake in Pelthos Therapeutics by 309.5% in the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company's stock valued at $7,928,000 after buying an additional 193,307 shares during the period. Boothbay Fund Management LLC increased its stake in shares of Pelthos Therapeutics by 279.8% in the 4th quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company's stock valued at $2,501,000 after acquiring an additional 59,435 shares in the last quarter. J. Goldman & Co LP acquired a new position in shares of Pelthos Therapeutics during the 4th quarter valued at $2,418,000. Cantor Fitzgerald L. P. bought a new position in Pelthos Therapeutics during the fourth quarter worth $1,085,000. Finally, Diadema Partners LP grew its holdings in Pelthos Therapeutics by 138.1% in the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company's stock worth $775,000 after purchasing an additional 14,502 shares during the period. Institutional investors own 77.96% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Oppenheimer upped their price target on shares of Pelthos Therapeutics from $60.00 to $62.00 and gave the stock an "outperform" rating in a report on Friday, March 20th. Zacks Research upgraded Pelthos Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 24th. Roth Mkm reduced their target price on Pelthos Therapeutics from $57.00 to $55.00 and set a "buy" rating on the stock in a report on Thursday, February 26th. HC Wainwright reissued a "buy" rating and set a $60.00 price target on shares of Pelthos Therapeutics in a report on Thursday, March 19th. Finally, Cantor Fitzgerald started coverage on Pelthos Therapeutics in a research report on Wednesday, April 1st. They set an "overweight" rating and a $50.00 price objective for the company. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Pelthos Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $55.00.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.